Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ADAMTS13を主成分とする診断薬および医薬品
Document Type and Number:
Japanese Patent JP7002727
Kind Code:
B2
Abstract:
New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.

Inventors:
Koichiro Hata
Shinji Uemoto
Hiroshi Hirao
Toyonari Kubota
Application Number:
JP2017560441A
Publication Date:
February 15, 2022
Filing Date:
January 06, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
KM Biologics Co., Ltd.
Kyoto University
International Classes:
G01N33/68; A61K38/48; A61P1/16; C07K14/47; C12N9/64; C12Q1/37; G01N33/50
Domestic Patent References:
JP2010280571A
JP2012103211A
JP2013505270A
Other References:
KO, S., et al.,Plasma ADAMTS13 Activity May Predict Early Adverse Events in Living Donor Liver Transplantation: Obs,Liver Transplantation,American association for the study of liver diseas,2006年05月,Vol.12/No.5,pp.859-869
KUME, Y. et al.,Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats,FEBS Letters,Elsevier B.V.,2007年03月20日,Vol.581,pp.1631-1634
UEMURA, M. et al.,Decreased Activity of Plasma ADAMTS13 May Contribute to the Development of Liver Disturbance and Mul,Alcoholism: clinical and experimental reserch,Research society on alcoholism,2005年12月,Vol.29/Supplement s3,pp.264S-271S
KANDUTSCH, S. et al.,Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases,European journal of surgical oncology,Elsevier Ltd.,2008年02月12日,Vol.34/No.11,pp.1231-1236
KHAN, A.Z. et al.,Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver,Journal of hepatobiliary pancreatic surgery,John Wiley & sons, Inc.,2008年12月18日,Vol.16/No.2,pp.137-144
RUBBIA-BRANDT, L. et al.,Severe hepatic sinusoidal obstruction associated with oxaliplatin-basedchemotherapy in patients with,Annals of oncology,European Society for Medical Oncology,2004年03月01日,Vol.15/No.3,pp.460-466
藤村吉博,他,動脈血栓症の制圧-VWF-GPIb軸依存性血小板血栓形成を調節するADAMTS13の基礎・臨床病態解析-,最新医学,最新医学社,2009年02月,Vol.64/No.2,pp.290-321
UEMURA, M. et al.,Pivotal role of ADAMTS13 function in liver diseases,International Journal of Hematology,2010年01月07日,Vol.91,p.20-29
HUGENHOLTZ, G.C.G., et al.,An Unbalance Between von Willebrand Factor and ADAMTS13 in Acute Liver Failure: Implications for Hem,Hepatology,American association for the study of liver diseas,2013年08月,Vol.58,pp.752-761
Attorney, Agent or Firm:
Yamato Kento
Norifumi Tomita
Shinichiro Yamanaka